Basaglar (insulin glargine) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to: improve blood sugar levels in adults ...
GoodRx, a resource for healthcare savings and information, is working with Sanofi, a company that specializes in diabetes care, to offer people living with diabetes access to Lantus (insulin glargine ...
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced it is working with Sanofi (NASDAQ: SNY), a global leader in ...
TREVOSE, Pa., Aug. 31, 2022 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that subject dosing has been completed in the pivotal clinical trial of biosimilar insulin glargine, a product ...
On November 18th, the U.S. Food and Drug Administration (FDA) announced its approval of Eli Lilly's Rezvoglar (insulin glargine-aglr) product as an interchangeable biosimilar to Sanofi's Lantus ...
* Says LixiLan to be based on the prefilled SoloSTAR pen platform, allowing for coverage of wide Lantus dosing needs and clinically relevant dosing of Lyxumia Source text for Eikon: ...
LONDON (Reuters) - The history of past drug scares suggests concerns over the safety of Sanofi-Aventis's diabetes treatment Lantus will hit sales, whether or not a suggested link to cancer proves real ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback